AUA 2017: Novel therapies targeting androgen receptor variant in an in vitro model of castrate resistant prostate cancer.
Boston, MA (UroToday.com) Joseph Baiocco presented on novel therapies targeting the androgen receptor variants in an in vivo model of castrate resistant prostate cancer. This study emphasized the importance of being able to provide further treatment for patients with androgen receptor variants in the setting of castrate resistant prostate cancer. Using novel compounds to inhibit the stabilization of the androgen receptor variation and lead to decreased castrate resistant prostate cancer cell viability and alteration in the androgen receptor variants. Additionally, because these androgen receptor variants become less viable they become more dependent on the use of glutaminolysis and fatty acid synthesis to survive. Thus, in addition to blocking glutaminolysis and fatty acid synthesis will also lead to castrate resistant prostate cancer cell death.
They found that their novel therapeutics responded in a dose-dependent decrease in the androgen receptor variants. In addition there was additive toxicity with combined therapeutics. They were able to demonstrate a reduction in the downstream transcriptional activity for ARv7 and ARFL. So overall they were able to successfully decrease the stability of the androgen receptor variants with the added combinations only increasing the in vivo response. This work represents a potential significant contribution to the furthering the treatment of castrate resistant prostate cancer.
Presented By: Joseph A. Baiocco
Written By: Janet Baack Kukreja (@janetkukreja), MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA